Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2022-01-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
• Collect exhaustive prospective data from patients eligible for oral immunotherapy.
This prospective observatory will enable statistical analyses to be carried out on common food allergens such as hazelnut, cashew nut, pistachio and others.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical and Biological Efficacy of Peanut Oral Immunotherapy
NCT02979600
Immunologic Profile of Children With Severe Allergies to Peanuts and Nuts After Induction of Tolerance
NCT01996774
Efficacy and Saffety of Oral Immunotherapy to Pistachio
NCT05698030
Endophenotyping for Plant-based Food Allergy Diagnosis, Tolerance Biomarkers, and Mechanisms in Microneedle Immunotherapy
NCT06997432
Threshold Dose Distribution for Pistachio Allergy
NCT06589232
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Depending on the allergen involved, the oral immunotherapy session will be assigned to one of three study groups: 1) allergen to hazelnut, walnut, pistachio, cashew or peanut,2) allergen to cow's milk, wheat or egg, 3) allergen to unusual foods: sesame, celery, fenugreek, peas, lentils, etc.
For each patient, and for each visit during the treatment period the collection of anthropometric, sociodemographic and medical data relating to oral food challenge will be done
Oral immunotherapy will then be started in accordance with standard practice. During this first visit, the investigator will give the patient a diary in which to record information about any IgE-mediated side-effects of the oral immunotherapy. Subsequent visits will follow the patient's usual routine until the desensitisation threshold is reached or the patient decides to stop the oral immunotherapy protocol. Visits will be made every 6 months, with a window of two months around each date.During these monitoring visits, tthe collection of anthropometric, sociodemographic and medical data relating to oral food challenge will be continue.
During each visit, a new food challenge test may be performed at the investigator's discretion to assess a new reactogenic threshold. Following this test, the following data will be collected:
* the cumulative dose ingested (mg food and mg food protein)
* the grade of the reaction (from 0 to 5 according to the Astier et Coll classification)
* achievement of desensitisation
A patient begins oral immunotherapy following food challenge test in a day hospital. Thus, a patient consulting at different times for several allergies and eligible for several oral immunotherapies will be able to take part in the study for several allergens. The follow-up of the different oral immunotherapies started (maximum 2 simultaneously, but could go up to 5, 6... over time) will be distinct. The patient may therefore participate several times in the study: in different groups, or in the same group, for different allergens. All the above data are collected separately for each new oral immunotherapy (except for socio-demographic data and information on previous oral immunotherapies, which are collected only at the time of inclusion).
In very rare cases, a patient may undergo several oral immunotherapies for the same allergen, but only the first oral immunotherapy (from the time the observatory was set up) will be taken into account in this study. If oral immunotherapy for the same allergen has already been carried out before the observatory was set up, the second oral immunotherapy for this allergen will not be included in the study, as its results will be biased.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Allergy to hazelnut, walnut, pistachio, cashew or peanut
Oral immunotherapy
Clinical Follow up
Group 2
Allergy to cow's milk, wheat or egg
Oral immunotherapy
Clinical Follow up
Group 3
Allergy to unusual foods: sesame, celery, fenugreek, peas, lentils or others
Oral immunotherapy
Clinical Follow up
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral immunotherapy
Clinical Follow up
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* positive diagnosis of food allergy (positive food challenge test or "highly probable allergy", defined by a convincing history, a positive prick test and IgE \> 0.35 kUA/L),
* eligible for oral food challenge
* accepting the following allergens : hazelnut, walnut, pistachio, cashew, peanut, cow's milk, wheat, egg, sesame, celery, fenugreek, pea, lentils or others
Exclusion Criteria
* Already received oral challenge for the same allergen.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lille Catholic University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tomas MORALY
Role: PRINCIPAL_INVESTIGATOR
Groupement des Hopitaux de l'institut catholique de Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Groupement de l'Institut Catholique de Lille - Hôpital Saint Vincent de Paul
Lille, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Tomas MORALY
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RNIPH-2021-36
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.